This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Repros Therapeutics® Receives IRB Approval To Commence Phase IIb Study Of Androxal® In The Treatment Of Secondary Hypogonadism

Repros Therapeutics Inc. ® (NasdaqCM:RPRX) today reported it has received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal ® in men with secondary hypogonadism. The Company has submitted the protocol for FDA comment and plans to begin enrolling subjects in January. Depending on the rate of subject enrollment, Repros hopes to have the study completed before the end of 2011.

The study will be conducted at up to 20 US clinical sites. Two sites in Texas have been initiated already and have commenced screening subjects. At this time the Company is planning to have sites in Houston and San Antonio, Texas; the metropolitan area of New York City; and San Diego, Los Angeles and Sacramento, California. The Company is also considering sites in Las Vegas, Nevada.

The study will enroll up to 120 men with morning testosterone levels < 250 ng/dl. The men must be naïve to testosterone therapy or have not used testosterone for at least six months. The men will be equally randomized to four different groups, double blind Androxal 12.5 mg and 25 mg, matching placebo and open label Testim used per manufacturer’s recommendations. Men will be dosed for three months.

The primary efficacy endpoint of the study is change in morning testosterone levels comparing the baseline visit to the levels achieved after three months to those achieved for placebo. Changes in pituitary hormones that control testicular function will be assessed as secondary efficacy measures.

Change in reproductive status as determined by semen analyses will be a safety endpoint as instructed by the FDA.

Analyses of previously completed studies by independent statisticians suggest that this study is well powered to achieve statistical significance for the primary and secondary efficacy endpoints. Those completed studies comparing Androxal to topical testosterone preparations showed statistically significant suppression of pituitary hormones that regulate testicular function by the replacement therapies. These findings suggest that the topical preparations will be viewed negatively when assessed from the perspective of reproductive status.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs